Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Adverse Drug Reaction Bulletin is Scopus-indexed (Q4, CiteScore 0.6). It is covered by India's One Nation One Subscription scheme for reading access. Published by Lippincott Williams and Wilkins.
Checked against the index lists dated .
ISSN 0044-6394Verify ISSN ↗2159-7774Verify ISSN ↗
Publisher: Lippincott Williams and Wilkins
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 242 / 278 | 13th | Q4 |
| Pharmacology | 287 / 328 | 12th | Q4 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1973–present (also 1970), best quartile Q4, CiteScore 0.6.
Adverse Drug Reaction Bulletin is Q4 in Pharmacology (medical) (rank 242 of 278) and Q4 in Pharmacology (rank 287 of 328), by CiteScore 2025.
Adverse Drug Reaction Bulletin is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 0.6, quartile Q4, 13th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.194, quartile Q4, with an H-index of 9.
Adverse Drug Reaction Bulletin is published by Lippincott Williams and Wilkins. Its print ISSN is 0044-6394 and its online ISSN is 2159-7774.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Adverse Drug Reaction Bulletin has an h-index of 14 and a 2-year mean of 0.39 citations per paper (OpenAlex). Its Scopus CiteScore is 0.6, quartile Q4. On 2-year citations it ranks #233 of 271 Scopus journals in Pharmacology (medical).
Adverse Drug Reaction Bulletin published 7 papers in 2025; its busiest recent year was 2017 with 8. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 34 research articles (2021–2026), authors are most often from Denmark (73.5%), United Kingdom (10.3%) and India (6.9%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.